HUAYAN ROBOTICS (01021.HK) has been included in the Hang Seng Composite Index and is expected to become a target stock for Stock Connect.
In early August, CMB International released a research report, giving Huayan Robotics a "Buy" rating with a target price of HKD 23.13.
On August 21, Hang Seng Indexes Company Limited announced the results of the 2026 second-quarter index review. Guangdong HUAYAN ROBOTICS Co., Ltd. (01021.HK) will be included in the Hang Seng Composite Index. This adjustment will officially take effect on September 7, 2026 (Monday), increasing the total number of constituents in the Hang Seng Composite Index from 534 to 580.
Being included in the Hang Seng Composite Index is an important prerequisite for becoming an investment target under the Stock Connect program. If the company is subsequently officially included in the Stock Connect, it will open a channel for southbound fund allocation to mainland investors, which will help enhance stock liquidity and market pricing efficiency.
HUAYAN ROBOTICS made its debut on the Hong Kong Stock Exchange main board on March 30 of this year. It is an industry-leading enterprise focused on core motion components for embodied intelligence and the R&D, production, and sales of collaborative Siasun Robots & Automation systems. With its full-stack self-developed technological capabilities and a rich product matrix, its products are widely used in various industries including 3C electronics, automotive, warehouse logistics, shipbuilding and heavy machinery, healthcare, semiconductors, food and daily chemicals, and AI infrastructure, establishing strong customer loyalty with numerous top domestic and international clients. In early August, BOCOM INTL released a research report giving HUAYAN ROBOTICS a "Buy" rating with a target price of HKD 23.13.
Related Articles

Zhejiang Shibao (01057) released its interim results, with a net profit attributable to shareholders of 104 million yuan, an increase of 11.48% year-on-year.

METIS TECHBIO-P (07666) has been included in the Hang Seng Composite Index, effective September 7.

AIM VACCINE (06660) announced its interim financial results, reporting revenue of 351 million yuan. It will continue to accelerate the commercialization and market preparation of its key products, including the iterative rabies vaccine series.
Zhejiang Shibao (01057) released its interim results, with a net profit attributable to shareholders of 104 million yuan, an increase of 11.48% year-on-year.

METIS TECHBIO-P (07666) has been included in the Hang Seng Composite Index, effective September 7.

AIM VACCINE (06660) announced its interim financial results, reporting revenue of 351 million yuan. It will continue to accelerate the commercialization and market preparation of its key products, including the iterative rabies vaccine series.

RECOMMEND





